ACAD Related Analyst Ratings
-
Needham & Company Maintains Bullish Stance on Acadia (ACAD)
-
Jefferies Maintains Bullish Stance on Acadia Pharmaceuticals (ACAD) after Management Meetings
-
Jefferies Raises Acadia Pharmaceuticals (ACAD) PT to $18 on Pimavanserin Win
-
Piper Jaffray Upgrades Acadia Pharmaceuticals (ACAD) to Overweight
-
Needham & Company Boosts PT on Acadia Pharmaceuticals (ACAD) by 78%
-
Jefferies Maintains Bullish Stance on Acadia Pharmaceuticals (ACAD) after AAN Meeting
-
Jefferies Maintains Bullish View on Acadia (ACAD) After Phase 3 Presentation
-
UPDATE: Jefferies Starts Acadia Pharmaceuticals (ACAD) at Buy; Attractive Takeover Target
-
Cowen Starts Acadia Pharmaceuticals (ACAD) at Outperform
-
Piper Jaffray Starts Acadia Pharmaceuticals (ACAD) at Neutral
-
UPDATE: Needham & Company Upgrades Acadia Pharmaceuticals (ACAD) to Buy, $9 Price Target
-
Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); Remaining Cautious on Pimavanserin
-
SunTrust Starts OPTR, ACAD, PCYC, TSRX, FURX, PYBI at Buy, ARQL at Neutral
-
Roth Capital Starts Acadia Pharmaceuticals (ACAD) at Buy
-
Ladenburg Thalmann Starts Acadia Pharmaceuticals (ACAD) at Buy
-
Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); Q4 Review: Pimavanserin Study 020 Results Expected in Late 3Q12
-
Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); 2012 Preview: Cautious in Front of Pimavanserin Phase 3 Results Expected in 3Q12
-
Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); Continues Enrolling Patients in its Phase 3 Trial of Pimavanserin
-
Needham & Company Maintains a 'Hold' on Acadia Pharmaceuticals (ACAD); 3Q10 Review
-
ACADIA Pharmaceuticals (ACAD) Shares Rise Sharply on Pimavanserin Update
-
Barclays Downgrades ACADIA (ACAD) to Equal Weight
-
Citi Downgrades ACADIA Pharmaceuticals (ACAD) to Sell
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Piper Jaffray Downgrades ACADIA Pharmaceuticals (ACAD) to Sell
-
JMP Downgrades ACADIA (ACAD) to Market Perform
-
Piper Jaffray Downgrades ACADIA Pharma (ACAD) to Neutral
-
BofA Upgrades Acadia Pharmaceuticals (ACAD) to Neutral
-
BofA Downgrades Acadia Pharmaceuticals (ACAD) to Sell
-
Needham Downgrades Acadia Pharma (ACAD) to Hold
-
JMP Securities Upgrades Acadia Pharmaceuticals (ACAD) to Strong Buy
-
ACADIA (ACAD) Added to Piper Jaffray's Alpha List
-
Brean Murray downgraded Acadia Pharmaceuticals (ACAD) to Sell
-
Citigroup Starts Acadia Pharmaceuticals (ACAD) at Hold
-
Deutsche Bank Initiates Coverage on Acadia Pharmaceuticals (ACAD) with a Buy
-
Friedman Billings Starts ACADIA Pharma (ACAD) at Outperform
-
Jim Cramer Makes Positive Comments on NSTK, ACAD and SNY
-
Jim Cramer makes positive comments on Acadia Pharmaceuticals Inc. (ACAD)
-
Brean Murray Said Market is Overreacting to Acadia Phama (ACAD) Trial Results
-
Fortis Starts ACADIA Pharmaceuticals (ACAD) at Buy
-
Brean Murray downgrades ACADIA Pharmaceuticals (ACAD) to Hold
-
Needham Starts Acadia Pharmaceuticals (ACAD) at Buy
-
Banc of America assumes coverage on Acadia Pharma (ACAD) at Buy
-
Banc of America Starts Acadia Pharmaceuticals (ACAD) at Buy
-
Brean Murray Starts ACADIA Pharmaceuticals (ACAD) at Strong Buy
-
Lehman Bros. Initiates Coverage on Acadia Pharmaceuticals (ACAD) with an Overweight
-
Piper Jaffray raises its price target on ACAD
-
Banc of America Starts ACAD at Buy
-
Adams Harnkess Starts ACAD at Buy
Back to ACAD Stock Lookup
